Salvus™ LLC is expecting its first commercial pathogen and chemical contamination detection devices to be delivered by December and anticipates clinical and market/demo trials to commence in early 2022.

Earlier this year, Salvus announced plans to commercialize a novel interferometric platform that provides highly accurate detection of contaminants or pathogens in many industries. Applicable in human and animal health, agriculture, water quality management, food processing and the chemical and transportation industries, Salvus detection technology features handheld detection in minutes with extreme specificity and at parts per billion accuracies in many applications.

The platform is proven to detect SARS-CoV-2, the virus that causes COVID-19, with sensitivity and specificity comparable to molecular tests, as well as dozens of other potentially dangerous pathogens and chemical contaminants.

Andre Weltman Tatar
Product Manager,
Salvus LLC

The Salvus detection system consists of a lightweight, handheld analyzer and a disposable cartridge – both patent pending – that is adaptable to many point-of-care and on-site uses ranging from airports and health care facilities to water containments, farm fields, food processing sites and animal enclosures.

Andre Weltman Tatar has joined Salvus as product manager and will be responsible for developing and implementing strategies, plans and tactics to create demand and enhance the growth and profitability of Salvus’ detection technology and business

Tatar is an industrial engineer with a Bachelor of Science degree in industrial and systems engineering from the Georgia Institute of Technology. A native of Brazil, Tatar is fluent in Portuguese, Spanish and English.

For more information on Salvus detection technology, go to salvusdetect.com.